Literature DB >> 7679683

Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables.

D W MacGlashan1.   

Abstract

Within the atopic and nonatopic population, basophils display a wide variation in the extent of histamine release when challenged with an optimal concentration of polyclonal anti-IgE antibody. We have tested the hypothesis that the maximum percent histamine release obtainable with this stimulus is an indicator of basophil sensitivity. We have defined basophil sensitivity, in the context of IgE-mediated release, as the number of cell-surface IgE molecules required to obtain a half-maximal IgE-mediated response, and we have examined this parameter in the basophils of 39 donors. Sensitizing basophils with various densities of antigen-specific IgE, and measuring histamine release at these measured densities, allowed a determination of basophil sensitivity in 38 of the donors. Basophil sensitivities ranged from 300 to 40,000 molecules per basophil (point of 50% maximal response), although most donors fell in the 800 to 8000 range, with 1900 molecules per basophil as the median response. The maximal response, after challenge with an optimal concentration of either polyclonal or monoclonal anti-IgE antibody, ranged from 8% to 94% (median, 50%). There was no correlation between basophil sensitivity and the maximum histamine release obtained by a challenge with anti-IgE antibody. Therefore two independent variables appeared to control the IgE-mediated response in basophils, similar to the parameters of efficacy and potency in drug studies. In the IgE-mediated response one parameter is the maximum histamine release obtainable through IgE-mediated mechanisms, and the second parameter is basophil sensitivity as defined above. As a byproduct of these studies, we also found that the density of unoccupied high-affinity receptors for IgE antibody was uncorrelated with the total receptor density (range, 4200 to 572,000 receptors per basophil). Indeed, the density of unoccupied receptors was remarkably constant across this large range of total receptor densities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679683     DOI: 10.1016/0091-6749(93)90266-i

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  20 in total

Review 1.  Mediators released during human anaphylaxis.

Authors:  Shelley F Stone; Simon G A Brown
Journal:  Curr Allergy Asthma Rep       Date:  2012-02       Impact factor: 4.806

Review 2.  IgE and FcepsilonRI regulation.

Authors:  Donald MacGlashan
Journal:  Clin Rev Allergy Immunol       Date:  2005-08       Impact factor: 8.667

3.  Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.

Authors:  Rui Zhu; Yanan Zheng; Wendy S Putnam; Jennifer Visich; Mark D Eisner; John G Matthews; Karin E Rosen; David Z D'Argenio
Journal:  AAPS J       Date:  2013-02-15       Impact factor: 4.009

4.  Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors.

Authors:  Donald W MacGlashan; Jessica H Savage; Robert A Wood; Sarbjit S Saini
Journal:  J Allergy Clin Immunol       Date:  2012-07-15       Impact factor: 10.793

Review 5.  Immunotherapy in allergy and cellular tests: state of art.

Authors:  Salvatore Chirumbolo
Journal:  Hum Vaccin Immunother       Date:  2014-05-02       Impact factor: 3.452

6.  Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab.

Authors:  Asifa K Zaidi; Sarbjit S Saini; Donald W Macglashan
Journal:  J Allergy Clin Immunol       Date:  2010-03-17       Impact factor: 10.793

7.  Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.

Authors:  Donald W Macglashan; Sarbjit S Saini
Journal:  J Allergy Clin Immunol       Date:  2013-06-20       Impact factor: 10.793

8.  Saturation of immunoglobulin E (IgE) binding sites by polyclonal IgE does not explain the protective effect of helminth infections against atopy.

Authors:  Edward Mitre; Stephanie Norwood; Thomas B Nutman
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

9.  Omalizumab: the evidence for its place in the treatment of allergic asthma.

Authors:  Diarmuid M McNicholl; Liam G Heaney
Journal:  Core Evid       Date:  2008-06

10.  A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.

Authors:  E Suzanne Cohen; Claire L Dobson; Helena Käck; Bing Wang; Dorothy A Sims; Christopher O Lloyd; Elizabeth England; D Gareth Rees; Hongwei Guo; Sophia N Karagiannis; Siobhan O'Brien; Sofia Persdotter; Helena Ekdahl; Robin Butler; Feenagh Keyes; Sarah Oakley; Mats Carlsson; Emmanuel Briend; Trevor Wilkinson; Ian K Anderson; Phillip D Monk; Karin von Wachenfeldt; Per-Olof F Eriksson; Hannah J Gould; Tristan J Vaughan; Richard D May
Journal:  MAbs       Date:  2014-02-28       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.